谱尼测试：2025年前三季度净利润约-1.99亿元

Group 1 - The core viewpoint of the article highlights the financial performance of Puni Testing, indicating a significant decline in revenue and a net loss for the third quarter of 2025 [1] - Puni Testing reported a revenue of approximately 932 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 17.01% [1] - The net profit attributable to shareholders was a loss of approximately 199 million yuan, with a basic earnings per share loss of 0.3644 yuan [1] Group 2 - The market capitalization of Puni Testing is currently valued at 4.4 billion yuan [1] - The article also discusses the broader context of the Chinese innovative drug market, noting that overseas licensing has generated sales of 80 billion USD this year [1] - There is a contrast presented between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [1]